TANDEM DIABETES CARE INC (TNDM) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does TANDEM DIABETES CARE INC Do?
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. TANDEM DIABETES CARE INC (TNDM) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO John F. Sheridan and employs approximately 2,600 people, headquartered in Wilmington, California. With a market capitalization of $1.3B, TNDM is one of the notable companies in the Healthcare sector.
TANDEM DIABETES CARE INC (TNDM) Stock Rating — Reduce (April 2026)
As of April 2026, TANDEM DIABETES CARE INC receives a Reduce rating with a composite score of 34.4/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TNDM ranks #3,696 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, TANDEM DIABETES CARE INC ranks #610 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
TNDM Stock Price and 52-Week Range
TANDEM DIABETES CARE INC (TNDM) currently trades at $19.30. The stock lost $0.38 (1.9%) in the most recent trading session. The 52-week high for TNDM is $29.65, which means the stock is currently trading -34.9% from its annual peak. The 52-week low is $9.98, putting the stock 93.4% above its annual trough. Recent trading volume was 926K shares, suggesting relatively thin trading activity.
Is TNDM Overvalued or Undervalued? — Valuation Analysis
TANDEM DIABETES CARE INC (TNDM) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 8.05x, versus the sector average of 2.75x. The price-to-sales ratio is 1.29x, compared to 1.66x for the average Healthcare stock.
At current multiples, TANDEM DIABETES CARE INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
TANDEM DIABETES CARE INC Profitability — ROE, Margins, and Quality Score
TANDEM DIABETES CARE INC (TNDM) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -146.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.8% versus the sector average of -33.1%.
On a margin basis, TANDEM DIABETES CARE INC reports gross margins of 51.9%, compared to 71.5% for the sector. The operating margin is -23.2% (sector: -66.1%). Net profit margin stands at -23.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 12.3% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
TNDM Debt, Balance Sheet, and Financial Health
TANDEM DIABETES CARE INC has a debt-to-equity ratio of 468.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.55x, indicating strong short-term liquidity. Total debt on the balance sheet is $310M. Cash and equivalents stand at $92M.
TNDM has a beta of 1.07, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for TANDEM DIABETES CARE INC is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.
TANDEM DIABETES CARE INC Revenue and Earnings History — Quarterly Trend
In TTM 2026, TANDEM DIABETES CARE INC reported revenue of $968M and earnings per share (EPS) of $-3.04. Net income for the quarter was $-227M. Gross margin was 51.9%. Operating income came in at $-222M.
In FY 2025, TANDEM DIABETES CARE INC reported revenue of $1.01B and earnings per share (EPS) of $-3.04. Net income for the quarter was $-205M. Gross margin was 53.8%. Revenue grew 7.9% year-over-year compared to FY 2024. Operating income came in at $-187M.
In Q3 2025, TANDEM DIABETES CARE INC reported revenue of $249M and earnings per share (EPS) of $-0.31. Net income for the quarter was $-21M. Gross margin was 53.9%. Revenue grew 2.2% year-over-year compared to Q3 2024. Operating income came in at $-23M.
In Q2 2025, TANDEM DIABETES CARE INC reported revenue of $241M and earnings per share (EPS) of $-0.78. Net income for the quarter was $-52M. Gross margin was 52.3%. Revenue grew 8.5% year-over-year compared to Q2 2024. Operating income came in at $-52M.
Over the past 8 quarters, TANDEM DIABETES CARE INC has demonstrated a growth trajectory, with revenue expanding from $222M to $968M. Investors analyzing TNDM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
TNDM Dividend Yield and Income Analysis
TANDEM DIABETES CARE INC (TNDM) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
TNDM Momentum and Technical Analysis Profile
TANDEM DIABETES CARE INC (TNDM) has a momentum factor score of 53/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 28/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
TNDM vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, TANDEM DIABETES CARE INC (TNDM) ranks #610 out of 838 stocks based on the Blank Capital composite score. This places TNDM in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing TNDM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TNDM vs S&P 500 (SPY) comparison to assess how TANDEM DIABETES CARE INC stacks up against the broader market across all factor dimensions.
TNDM Next Earnings Date
No upcoming earnings date has been announced for TANDEM DIABETES CARE INC (TNDM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy TNDM? — Investment Thesis Summary
The quantitative profile for TANDEM DIABETES CARE INC suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. High volatility (stability score 34/100) increases portfolio risk.
In summary, TANDEM DIABETES CARE INC (TNDM) earns a Reduce rating with a composite score of 34.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TNDM stock.
Related Resources for TNDM Investors
Explore more research and tools: TNDM vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TNDM head-to-head with peers: TNDM vs AZN, TNDM vs SLGL, TNDM vs VMD.